• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form NT 10-Q filed by Rite Aid Corporation

    1/12/24 5:00:11 PM ET
    $RAD
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples
    Get the next $RAD alert in real time by email
    NT 10-Q 1 tm243259d1_nt10q.htm NT 10-Q

     

     

    SEC FILE NUMBER

    001-05742

     

    CUSIP NUMBER

    767754872

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    FORM 12b-25 

     

     

     

    NOTIFICATION OF LATE FILING

     

    (Check One):  

    ¨ Form 10-K ¨ Form 20-F ¨ Form 11-K x Form 10-Q

    ¨ Form 10-D ¨ Form N-CEN ¨ Form N-CSR

     

        For Period Ended: December 2, 2023
       
        ¨ Transition Report on Form 10-K
       
        ¨ Transition Report on Form 20-F
       
        ¨ Transition Report on Form 11-K
       
        ¨ Transition Report on Form 10-Q
       
        For the Transition Period Ended: Not applicable

     

    Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

     

    If the notification relates to a portion of the filing checked above, identify the Item(s) to which the notification relates:

     

     

     

     

    PART I—REGISTRANT INFORMATION

     

    Rite Aid Corporation

    Full Name of Registrant

     

    Not applicable

    Former Name if Applicable

     

    P.O. Box 3165

    Address of Principal Executive Office (Street and Number)

     

    Harrisburg, Pennsylvania 17105

    City, State and Zip Code

     

    PART II—RULES 12b-25(b) AND (c)

     

    If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate)

     

     ¨     (a)   The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
      (b)   The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-CEN or Form N-CSR, or portion thereof, will be filed on or before the fifteenth calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q or subject distribution report on Form 10-D, or portion thereof, will be filed on or before the fifth calendar day following the prescribed due date; and
      (c)   The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

     

     

     

     

    PART III—NARRATIVE

     

    State below in reasonable detail why Form 10-K, 20-F, 11-K, 10-Q, 10-D, N-CEN, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period.

     

    Rite Aid Corporation (the “Company,” “we” or “our”) has determined that it is unable to file, without unreasonable effort or expense, its Quarterly Report on Form 10-Q for the fiscal quarter ended December 2, 2023 (the “Q3 Form 10-Q”) by the prescribed due date for the reasons described below.

     

    As previously disclosed, on October 15, 2023, the Company and certain of its direct and indirect subsidiaries filed voluntary petitions to commence proceedings under chapter 11 (the “Chapter 11 Cases”) of title 11 of the United States Code in the United States Bankruptcy Court for the District of New Jersey. Due to the considerable time and resources needed to address the ongoing Chapter 11 Cases, and the resulting diversion of the attention of the Company’s management and other personnel responsible for preparation of the Q3 Form 10-Q, the Company is unable to file the Q3 Form 10-Q within the prescribed time period.

     

    In addition, during the Company’s preparation of its financial statements for the third fiscal quarter ended December 2, 2023, the Company’s management preliminarily identified a misapplication of U.S. GAAP relating to the Company’s methodology of recording provisional closed store charges, prompting the need for further analysis under Accounting Standards Codification Topic 420 (“ASC Topic 420”). The Company’s management has preliminarily determined that the impact of such misapplication on previously issued financial statements is not material and is still evaluating the impact on internal control over financial reporting (“ICFR”). The resolution of this matter may result in the Company filing amendments to its Form 10-K for the fiscal year ended March 4, 2023 and its Form 10-Q for the fiscal quarters ended June 3, 2023 and September 2, 2023, respectively. The Company’s management has discussed this matter with Deloitte & Touche LLP, the Company’s independent registered public accounting firm.

     

    The Company has been working diligently to finalize this review; however, given the added complexity of the Chapter 11 Cases, the Company was unable to complete and file the Q3 Form 10-Q by the prescribed due date without unreasonable effort and expense. The Company currently anticipates filing the Q3 Form 10-Q as promptly as practicable following the resolution of the above noted review; however, there can be no assurance as to when the Company will be able to file the Q3 Form 10-Q.

     

     

     

     

    Forward-Looking Statements

     

    Certain matters discussed in this Form 12b-25 constitute forward-looking statements within the meaning of the federal securities laws. All statements contained in this notification, other than statements of historical fact, are forward-looking statements, including, without limitation, statements regarding the anticipated timing of the filing of the Q3 Form 10-Q; expectations with regard to the anticipated impact of the misapplication; the Company’s preliminary analysis with respect to ASC Topic 420 and the Company’s ICFR; and any assumptions underlying any of the foregoing.

     

    These forward-looking statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Important factors that could cause actual results to differ materially from expectations include, but are not limited to, the effectiveness of the Company’s ICFR and disclosure controls and procedures; the potential for a material weakness in the Company’s ICFR or other potential control deficiencies of which the Company is not currently aware; the risk that the completion and filing of the Q3 Form 10-Q will take longer than expected; additional information that may arise during the finalization of the Q3 Form 10-Q; our ability to obtain a waiver from the lenders party to our debtor-in-possession credit facilities (holding a majority of our outstanding borrowings thereunder) as a consequence of our inability to timely provide financial statements, as well as the modifications that may be required of past compliance certifications that we have provided to such lenders; and the risks discussed in detail in Item 1A. Risk Factors of the Company’s most recent Annual Report on Form 10-K, in the Company’s subsequent Quarterly Reports on Form 10-Q, and in other documents that we file or furnish with the Securities and Exchange Commission. The Company undertakes no obligation to update publicly any forward-looking statements, whether as a result of future events, new information or otherwise, except as required by law.

     

     

     

     

    PART IV—OTHER INFORMATION

     

                             
    (1)       Name and telephone number of person to contact in regard to this notification
                 
            Matthew C. Schroeder       (717)       761-2633
            (Name)       (Area Code)       (Telephone Number)
         
    (2)      

    Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If answer is no, identify report(s).

     

    Yes x No ¨

     

         
    (3)      

    Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof ?

     

    Yes x No ¨

     

         
            If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

     

    When the Company completes the preparation of the Q3 Form 10-Q, including the application of Financial Accounting Standards Board Accounting Standards Codification (“ASC”) Topic 852 – Reorganizations, which specifies the accounting and financial reporting requirements for entities reorganizing through Chapter 11 bankruptcy proceedings, as well as any impact of the misapplication of ASC 420 discussed in Part III above, the Company expects to report a significant increase in net loss for the quarter ended December 2, 2023, as compared to the corresponding quarter ended November 26, 2022. Such increase would result in part from an increase in impairment charges resulting from store closures and higher professional expenses.

     

     

     

     

    Rite Aid Corporation

    (Name of Registrant as Specified in Charter)

     

    has caused this notification to be signed on its behalf by the undersigned hereunto duly authorized.

     

         
    Date: January 12, 2024 By: /s/ Matthew C. Schroeder
        Matthew C. Schroeder
        Executive Vice President and Chief Financial Officer

     

     

    Get the next $RAD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $RAD

    DatePrice TargetRatingAnalyst
    4/7/2022$16.00 → $1.00Hold → Sell
    Deutsche Bank
    6/25/2021$21.00 → $12.00Neutral → Underweight
    JP Morgan
    More analyst ratings

    $RAD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Carenet Health Acquiring Health Dialog, Enhancing Clinical Team and Advancing Insights-Driven Platform Dedicated to the Business of Healthcare

      Expanded personalized population health capabilities support better health journeys for patients Carenet Health, a trusted partner in helping organizations simplify and power the business of healthcare, is excited to announce it is acquiring Health Dialog, a worldwide leader in delivering clinical decision support offerings. This acquisition enables Carenet to leverage its combined platform, analytics and clinicians to deliver greater efficiency and outcomes-based financial performance for clients. Health Dialog provides personalized population health services to health plans, providers, employers and pharmaceutical manufacturers. Carenet is acquiring all assets of Health Dialog from

      3/6/24 11:05:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Receives Court Approval of "First Day" Motions to Support Business Operations

      Secures Interim Approval to Access Up to $3.45 Billion in Debtor-in-Possession Financing Continues to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (OTC:RADCQ) ("Rite Aid" or the "Company") today announced that it has received approvals from the U.S. Bankruptcy Court for the District of New Jersey for its "First Day" motions related to the Company's voluntary Chapter 11 petitions filed on October 15, 2023. The Court granted interim approval to access up to $3.45 billion in debtor-in-possession financing from certain of its lenders. This financing is expected to provide sufficient liquidity to support the Company th

      10/17/23 11:05:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

      Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Leadership Updates

    Live Leadership Updates

    See more

    $RAD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rite Aid Corporation Appoints Jeffrey S. Stein Chief Executive Officer

      Stein Succeeds Elizabeth "Busy" Burr Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced that its Board of Directors has appointed Jeffrey S. Stein as Chief Executive Officer (CEO), Chief Restructuring Officer (CRO) and a member of the Board of Directors, effective immediately. Mr. Stein succeeds Elizabeth ("Busy") Burr, who has served as Interim CEO of Rite Aid since January 2023. Ms. Burr will continue to serve on the Company's Board. Mr. Stein brings more than three decades of experience as a leader and executive director at both public and private companies. Mr. Stein has particular expertise in supporting companies that are driving meaningful business tran

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Takes Steps to Accelerate Transformation and Position Company for Long-Term Success

      Reaches Agreement in Principle with Key Creditors on the Terms of Financial Restructuring Plan Initiates Voluntary Chapter 11 Process to Implement a Consensual Financial Restructuring That Will Significantly Reduce Debt and Enable Execution of Key Initiatives Receives Commitment for $3.45 Billion in New Financing to Support Business Operations Continuing to Serve Customers and Deliver Healthcare Products and Services Across Retail and Online Platforms Rite Aid Corporation (NYSE:RAD) ("Rite Aid" or the "Company") today announced it has reached an agreement in principle with certain of its senior secured noteholders on the terms of a financial restructuring plan that will allow the Co

      10/15/23 10:37:00 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid downgraded by Deutsche Bank with a new price target

      Deutsche Bank downgraded Rite Aid from Hold to Sell and set a new price target of $1.00 from $16.00 previously

      4/7/22 7:32:45 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid downgraded by JP Morgan with a new price target

      JP Morgan downgraded Rite Aid from Neutral to Underweight and set a new price target of $12.00 from $21.00 previously

      6/25/21 7:27:02 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Deutsche Bank reiterated coverage on Rite Aid with a new price target

      Deutsche Bank reiterated coverage of Rite Aid with a rating of Hold and set a new price target of $27.00 from $17.00 previously

      3/25/21 9:26:08 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3: New insider Dupaul Christopher W. claimed ownership of 34,525 shares

      3 - RITE AID CORP (0000084129) (Issuer)

      8/24/23 4:33:34 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Schroeder Matt

      4 - RITE AID CORP (0000084129) (Issuer)

      7/28/23 4:10:16 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form 4 filed by Mennen Justin L.

      4 - RITE AID CORP (0000084129) (Issuer)

      7/28/23 4:09:48 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Financials

    Live finance-specific insights

    See more
    • Rite Aid Corporation Reports Fiscal 2024 First Quarter Results

      Revenues of $5.7 Billion, Compared to Prior Year Revenues of $6.0 Billion Retail Comparable Same Store Prescriptions Increased 4.7 Percent – Comparable Same Store Prescriptions, Excluding COVID Impact, Increased 7.4 Percent Net Loss of $306.7 Million Compared to Prior Year Net Loss of $110.2 Million – Increase Largely Attributable to a Goodwill Impairment Charge at Elixir Adjusted EBITDA of $91.7 Million, Compared to Prior Year Adjusted EBITDA of $100.1 Million Updates Fiscal 2024 Outlook Rite Aid Corporation (NYSE:RAD) today reported operating results for its first fiscal quarter ended June 3, 2023. "Our first quarter results were driven by strong script growth, solid ph

      6/29/23 7:00:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid to Release First Quarter Results on June 29

      Rite Aid Corporation (NYSE:RAD) will release financial results for its Fiscal 2024 First Quarter, which ended June 3, 2023, on Thursday, June 29, 2023. The company will hold an analyst call at 8:30 a.m. ET with remarks by Rite Aid's management team. The call will be broadcast at https://investors.riteaid.com. The telephone replay will be available beginning at 12:00 p.m. ET on Thursday, June 29, 2023, through 11:59 p.m. ET on July 29, 2023. To access the replay of the call, please dial (800) 770-2030 or (647) 362-9199 and enter the seven-digit reservation number 9029129. The webcast replay of the call will also be available at https://investors.riteaid.com starting at 12 p.m. ET Thursda

      6/12/23 8:30:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation Reports Fiscal 2023 Fourth Quarter and Full Year Results and Provides Fiscal 2024 Outlook

      Fourth Quarter Highlights: Revenues of $6.1 billion, Comparable to Prior Year Retail Comparable Same Store Prescriptions Increased 5.2 Percent – Comparable Same Store Prescriptions, Excluding COVID Impacts, Increased 9.7 Percent Net Loss per Share of $4.39, Compared to Prior Year Net Loss per Share of $7.18 Adjusted EBITDA of $128.6 million, Compared to the Prior Year Adjusted EBITDA of $106.1 million Completed Tender Offer for $165 million of our 2025 notes – Reducing Amount Outstanding to $320 million From $600 million at Beginning of Fiscal 2022 Full Year Highlights: Revenues of $24.1 billion, Compared to Prior Year Revenues of $24.6 billion Retail Comparable Same

      4/20/23 7:00:00 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    SEC Filings

    See more
    • SEC Form NT 10-Q filed by Rite Aid Corporation

      NT 10-Q - RITE AID CORP (0000084129) (Filer)

      1/12/24 5:00:11 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Bankruptcy or Receivership, Other Events, Financial Statements and Exhibits

      8-K - RITE AID CORP (0000084129) (Filer)

      12/27/23 6:03:09 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • Rite Aid Corporation filed SEC Form 8-K: Entry into a Material Definitive Agreement, Financial Statements and Exhibits

      8-K - RITE AID CORP (0000084129) (Filer)

      11/1/23 4:30:23 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples

    $RAD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      2/9/23 11:32:52 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      7/11/22 1:13:14 PM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples
    • SEC Form SC 13G/A filed by Rite Aid Corporation (Amendment)

      SC 13G/A - RITE AID CORP (0000084129) (Subject)

      3/9/22 8:44:09 AM ET
      $RAD
      Retail-Drug Stores and Proprietary Stores
      Consumer Staples